152 related articles for article (PubMed ID: 37365634)
1. Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma.
Cascini C; Ratti C; Botti L; Parma B; Cancila V; Salvaggio A; Meazza C; Tripodo C; Colombo MP; Chiodoni C
J Exp Clin Cancer Res; 2023 Jun; 42(1):154. PubMed ID: 37365634
[TBL] [Abstract][Full Text] [Related]
2. Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4
Gallotta M; Assi H; Degagné É; Kannan SK; Coffman RL; Guiducci C
Cancer Res; 2018 Sep; 78(17):4943-4956. PubMed ID: 29945961
[TBL] [Abstract][Full Text] [Related]
3.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
4. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy.
Zhang H; Liu L; Yu D; Kandimalla ER; Sun HB; Agrawal S; Guha C
PLoS One; 2012; 7(5):e38111. PubMed ID: 22666458
[TBL] [Abstract][Full Text] [Related]
5. EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy.
Kapp K; Volz B; Curran MA; Oswald D; Wittig B; Schmidt M
J Immunother Cancer; 2019 Jan; 7(1):5. PubMed ID: 30621769
[TBL] [Abstract][Full Text] [Related]
6. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Sato-Kaneko F; Yao S; Ahmadi A; Zhang SS; Hosoya T; Kaneda MM; Varner JA; Pu M; Messer KS; Guiducci C; Coffman RL; Kitaura K; Matsutani T; Suzuki R; Carson DA; Hayashi T; Cohen EE
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931759
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
8. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.
Reilley MJ; Morrow B; Ager CR; Liu A; Hong DS; Curran MA
J Immunother Cancer; 2019 Nov; 7(1):323. PubMed ID: 31771649
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
Karan D; Krieg AM; Lubaroff DM
Int J Cancer; 2007 Oct; 121(7):1520-8. PubMed ID: 17565748
[TBL] [Abstract][Full Text] [Related]
11. TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasis.
Xu A; Zhang L; Yuan J; Babikr F; Freywald A; Chibbar R; Moser M; Zhang W; Zhang B; Fu Z; Xiang J
Cell Mol Immunol; 2019 Oct; 16(10):820-832. PubMed ID: 30467420
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
[TBL] [Abstract][Full Text] [Related]
13. Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist.
Fend L; Gatard-Scheikl T; Kintz J; Gantzer M; Schaedler E; Rittner K; Cochin S; Fournel S; Préville X
Cancer Immunol Res; 2014 Dec; 2(12):1163-74. PubMed ID: 25168392
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
15. Aspect ratio-dependent dual-regulation of the tumor immune microenvironment against osteosarcoma by hydroxyapatite nanoparticles.
Wu H; Wang R; Li S; Chen S; Liu S; Li X; Yang X; Zeng Q; Zhou Y; Zhu X; Zhang K; Tu C; Zhang X
Acta Biomater; 2023 Oct; 170():427-441. PubMed ID: 37634831
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer.
Carbone C; Piro G; Agostini A; Delfino P; De Sanctis F; Nasca V; Spallotta F; Sette C; Martini M; Ugel S; Corbo V; Cappello P; Bria E; Scarpa A; Tortora G
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479922
[TBL] [Abstract][Full Text] [Related]
17. TLR9 blockade inhibits activation of diabetogenic CD8+ T cells and delays autoimmune diabetes.
Zhang Y; Lee AS; Shameli A; Geng X; Finegood D; Santamaria P; Dutz JP
J Immunol; 2010 May; 184(10):5645-53. PubMed ID: 20393135
[TBL] [Abstract][Full Text] [Related]
18. Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.
Vibholm L; Schleimann MH; Højen JF; Benfield T; Offersen R; Rasmussen K; Olesen R; Dige A; Agnholt J; Grau J; Buzon M; Wittig B; Lichterfeld M; Petersen AM; Deng X; Abdel-Mohsen M; Pillai SK; Rutsaert S; Trypsteen W; De Spiegelaere W; Vandekerchove L; Østergaard L; Rasmussen TA; Denton PW; Tolstrup M; Søgaard OS
Clin Infect Dis; 2017 Jun; 64(12):1686-1695. PubMed ID: 28329286
[TBL] [Abstract][Full Text] [Related]
19. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
Brody JD; Ai WZ; Czerwinski DK; Torchia JA; Levy M; Advani RH; Kim YH; Hoppe RT; Knox SJ; Shin LK; Wapnir I; Tibshirani RJ; Levy R
J Clin Oncol; 2010 Oct; 28(28):4324-32. PubMed ID: 20697067
[TBL] [Abstract][Full Text] [Related]
20. Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity.
Masuda Y; Nawa D; Nakayama Y; Konishi M; Nanba H
J Leukoc Biol; 2015 Dec; 98(6):1015-25. PubMed ID: 26297795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
